/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Soligenix Inc, share price today is $1.24, up -0.81%. The stock opened at $1.22 against the previous close of $1.23, with an intraday high of $1.26 and low of $1.2.

style

pb-0

Soligenix Inc,

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$1.24 -0.0081(-0.81%) SNGX at 13 Mar 2026 03:17 PM Biotechnology

Lowest Today 1.2

Highest Today 1.26

Today’s Open 1.22

Prev. Close 1.23

52 Week High 6.23

52 Week Low 1.02

Day’s Range: Low 1.2 High 1.26

52-Week Range: Low 1.02 High 6.23

Soligenix Inc, Institutional Holdings

Soligenix Inc, Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Soligenix Inc, Fundamentals

Market Cap 12.41 M

PB Ratio 1.6328

PE Ratio 0.0

Enterprise Value 2.27 M

Total Assets 8.97 M

Volume 137232

Soligenix Inc, Company Financials

Annual Revenue FY23:960615 1.0M, FY22:948911 0.9M, FY21:824268 0.8M, FY20:2359447 2.4M, FY19:4629916 4.6M

Annual Profit FY23:304248 0.3M, FY22:398089 0.4M, FY21:95628 0.1M, FY20:538498 0.5M, FY19:1062501 1.1M

Annual Net worth FY23:-8074390 -8.1M, FY22:-13798339 -13.8M, FY21:-12550973 -12.6M, FY20:-17688522 -17.7M, FY19:-9355592 -9.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:2342 0.0M

Quarterly Profit Q3/2025:0 0.0M, Q2/2025:-703 -0.0M, Q1/2025:-608 -0.0M, Q3/2024:0 0.0M, Q2/2024:-1588 -0.0M

Quarterly Net worth Q3/2025:-2530947 -2.5M, Q2/2025:-2701976 -2.7M, Q1/2025:-3236763 -3.2M, Q3/2024:-1719381 -1.7M, Q2/2024:-1644502 -1.6M

About Soligenix Inc, & investment objective

Company Information Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Organisation Biotechnology

Employees 14

Industry Biotechnology

CEO Dr. Christopher J. Schaber Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*